Want to see PL:CTX full AI Analyst Report?
Captor Therapeutics SA (CTX) AI Stock Analysis
Captor Therapeutics SA
(Warsaw:CTX)
Captor Therapeutics SA’s stock score is severely constrained by its poor financial performance, led by worsening profitability, cash flow, and revenue decline. With no dividend, a negative P/E ratio, and no supportive technical data, the main risks are deep operational losses and high cash burn. The balance sheet is a relative bright spot but does not offset severe ongoing losses. There is no evidence of a near-term turnaround.
Captor Therapeutics SA (CTX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- PLN 318.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 5,299
- Price to Earnings (P/E)
- -6.5
- Beta (1Y)
- 0.37
- Revenue Growth
- -81.93%
- EPS Growth
- -3.31%
- Country
- PL
- Employees
- 82
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Captor Therapeutics SA Business Overview & Revenue Model
Company Description
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes man...
How the Company Makes Money
Captor Therapeutics generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies, which provide funding for research and development efforts. These partnerships often include upfront payments, milestone...
Captor Therapeutics SA Financial Statement Overview
Summary
Financial performance is extremely weak. Revenue continues to decline, gross profit margin has collapsed from 77% to 41%, and net profit margin is deeply negative at -243%. Operating and free cash flows remain sharply negative, with cash flow worsening and high risk of depleting capital reserves. Although the balance sheet shows low leverage and high equity, persistent losses and negative returns on equity are severe issues for investors.
Income Statement
23NegativeBalance Sheet
67PositiveCash Flow
21Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.01M | 4.66M | 15.82M | 13.20M | 9.16M | 3.99M |
| Gross Profit | 2.14M | -652.00K | 6.42M | 6.90M | 7.07M | 3.25M |
| EBITDA | -45.96M | -48.84M | -32.93M | -64.76M | -28.22M | -24.41M |
| Net Income | -44.28M | -42.00M | -38.43M | -70.58M | -35.89M | -32.57M |
Balance Sheet | ||||||
| Total Assets | 79.54M | 40.02M | 87.50M | 97.29M | 113.00M | 143.54M |
| Cash, Cash Equivalents and Short-Term Investments | 71.50M | 32.11M | 39.26M | 75.70M | 90.89M | 117.94M |
| Total Debt | 2.66M | 3.58M | 5.64M | 3.78M | 6.95M | 8.18M |
| Total Liabilities | 14.47M | 16.54M | 23.02M | 28.07M | 16.68M | 19.34M |
| Stockholders Equity | 65.06M | 23.48M | 64.47M | 69.22M | 96.32M | 124.20M |
Cash Flow | ||||||
| Free Cash Flow | -73.75M | -36.53M | -32.06M | -55.21M | -23.84M | -33.59M |
| Operating Cash Flow | -73.39M | -36.32M | -31.64M | -52.20M | -22.95M | -28.47M |
| Investing Cash Flow | -33.26M | -21.14M | 273.00K | 19.93M | -17.63M | -5.11M |
| Financing Cash Flow | 93.86M | 28.92M | -4.84M | 36.94M | -6.33M | 140.88M |
Captor Therapeutics SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:CTX, the sentiment is Negative. The current price of 55.00 is below the 20-day moving average (MA) of 57.00, below the 50-day MA of 65.18, and below the 200-day MA of 74.76, indicating a bearish trend. The MACD of -4.14 indicates Positive momentum. The RSI at 19.20 is Positive, neither overbought nor oversold. The STOCH value of 13.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PL:CTX.
Captor Therapeutics SA Peers Comparison
Overall Rating
PL:SLV40Underperform
PL:RVU37Underperform- PL:CTX34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| PL:SLV | 40Underperform | PLN 291.85M | -132.40 | -0.66% | ― | -8.26% | -548.22% |
| PL:RVU | 37Underperform | PLN 372.23M | -5.50 | -139.66% | ― | -11.57% | 43.60% |
| PL:CTX | 34Underperform | PLN 318.75M | -6.55 | -132.32% | ― | -81.93% | -3.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PL:CTX | Captor Therapeutics SA | 55.00 | 10.00 | 22.22% | |
| PL:RVU | Ryvu Therapeutics SA | 16.82 | -6.13 | -26.71% | |
| PL:SVE | Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. | 2.58 | -1.49 | -36.61% | |
| PL:MOC | OncoArendi Therapeutics SA | 5.57 | -0.55 | -8.99% | |
| PL:SLV | Selvita SA | 16.40 | -23.90 | -59.31% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 16, 2025